 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
Sonic Innovations designs and makes hearing aids using its digital signal processing (DSP) technology. It has two primary products: the NATURA hearing aid, which has a conventional fit, and the CONFORMA hearing aid, which fits entirely within the ear canal. Sonic Innovations also sells components of its DSP technology to other hearing aid companies. The US accounts for almost 70% of the company's sales; its products are marketed in Europe through subsidiary Sonic Innovations A/S and in Japan through an agreement with Hoya Healthcare Corporation. Major customers include Starkey Laboratories and Rion Company. The company's investors include Venrock Associates, Accel Partners, and New Enterprise Associates. Revenue growth Q2Q is good but company has not shown a profit. Revs 2.1M to 3.2M to 5.6M to 8.4M to 11.5M Dec99 SALT LAKE CITY--(BUSINESS WIRE)--May 1, 2000--Sonic Innovations, Inc. (Nasdaq:SNCI) today announced the initial public offering of 3,600,000 shares of common stock at a price of $14.00 per share, all of which are being offered by Sonic Innovations, Inc. The shares will trade on the Nasdaq National Market under the symbol "SNCI". Goldman, Sachs & Co. led the offering, with Deutsche Banc Alex. Brown and U.S. Bancorp Piper Jaffray co-managing the offering. The underwriters have been granted a 30-day over allotment option to purchase up to an additional 540,000 shares of common stock from the company. Based in Salt Lake City, Sonic Innovations designs, manufactures and markets advanced digital hearing aids designed to provide the highest levels of satisfaction for hearing-impaired consumers. Capitalizing on a new understanding of human hearing, the company developed patented digital signal processing (DSP) technologies and embedded them in the smallest, single-chip DSP platform ever installed in a hearing aid. This technological advantage helps set a new standard for consumer satisfaction and delivers more natural sound than competing hearing aids. Sonic Innovations' products are based on algorithms and technology developed by Dr. Douglas Chabries, Dean of the College of Engineering and Technology at Brigham Young University; Dr. Thomas Stockham, widely regarded as the father of digital recording; and Dr. Carver Mead, Professor of Computer Science at the California Institute of Technology. To learn more about Sonic Innovations, visit www.sonici.com. A registration statement relating to these securities has been filed with and declared effective by the Securities and Exchange Commission. This announcement shall not constitute an offer to sell or the solicitation of an offer to buy the common stock of Sonic Innovations, Inc., nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the final prospectus related to the offering may be obtained from Goldman, Sachs & Co., 85 Broad Street, New York, New York 10004, 212/902-1000, Deutsche Banc Alex. Brown, One South Street, Baltimore MD 21202, 410/895-2070 and U.S. Bancorp Piper Jaffray, 800 Nicolette Mall Suite 800, Minneapolis MN 55402-7020, 612/303-6000. From the S1 Our technology strategy is to combine a number of distinct technologies, supported by over 30 patents and patent applications, to produce premium digital products. The core of our technology is our proprietary digital signal processing, or DSP, technologies, which are based on a significant advancement in the understanding of human hearing. Using state-of-the-art chip design capabilities, we have embedded our proprietary algorithms into the smallest, single-chip DSP platform available in a hearing aid today. As a result, our NATURA products are among the smallest hearing aids available, and our CONFORMA product is the smallest hearing aid available today. Our CONFORMA product is the first product with the potential to address all of the major limitations of traditional hearing aids and significantly alter the way hearing aids are made and sold. CONFORMA, a programmable completely-in-the-canal model, introduces a new, innovative hearing aid configuration that delivers a fast, comfortable fit in the smallest hearing aid available. This small size allows it to be placed deep in the ear canal, virtually eliminating the stigma of wearing a hearing aid. Shares to be offered by Sonic Innovations..... 3,600,000 shares Shares outstanding after the offering......... 18,914,572 shares EPS loss per year $ (2.26) $ (3.21) $ (8.23) $ (15.61) $ (12.72) Dec99 These losses and negative cash flows resulted primarily from expenses we incurred while developing our initial hearing aid products and establishing an infrastructure to support our business. We have not achieved profitability. We encounter aggressive competition from over 30 competitors worldwide, many of which have far greater sales and more extensive financial and business resources than we have. Our competitors range from some of the world's largest companies, such as Siemens GmbH, to many specialized firms, such as Starkey Laboratories, Inc. and Oticon A/S, as well as many smaller hearing aid companies. Jack | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2026 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |